In summary, large panels of targeted NGS or allele-specific assays targeting hotspot mutations are required for early detection, and ctDNA combined with other biomarkers (AFP or other novel circulating molecular biomarkers) may play a crucial supplementary role as a diagnostic biomarker in HCC. Here, AFP is linked to hepatocellular carcinoma.